Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "Ibrutinib"

Study identifies rational drug combinations that may overcome mantle cell lymphoma resistance to ibrutinib
Ecancer Medicalscience

Study identifies potential drug combination for mantle cell ly...

Using the molecularly targeted drug ibrutinib (Imbruvica) together with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), according to preclinical ... Ecancer Medicalscience, 10 hours ago
A Solution to Ibrutinib Resistance in MCL? American Journal of Public Health, 1 month ago
[x]  

6 images for Ibrutinib

SearchBug, 1 month ago
Drug Discovery and Development, 1 month ago
Ecancer Medicalscience, 1 month ago
Examiner.com, 1 month ago
OncLive, 1 month ago
Scottrade, 1 month ago

Evolution of ibrutinib resistance [Evolution]

A. Burger c , and Dominik Wodarz a , b a Department of Mathematics and b Department of Ecology and Evolutionary Biology, University of California, Irvine , CA 92697; and c Department of Leukemia, MD Anderson Cancer Center , Houston, TX 77230 ...
 PNAS2 weeks ago
Examiner.com

Imbruvica gains breakthrough status for treating chronic lymphocytic leukemia

The FDA has expanded the use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), and thus have shown poor responses to standard treatment for the disease. The news ...
 Examiner.com1 month ago Imbruvica Approved for Expanded Use and New Labeling  Pharmacy Times1 month ago FDA Expands Use of Imbruvica for Form of Leukemia  US News & World Report1 month ago Imbruvica expands label  Seeking Alpha1 month ago
[x]  
Pharma Letter

Combination of ibrutinib, rituximab induced responses in high-risk CLL

Patients with high-risk chronic lymphocytic leukemia demonstrated encouraging rates of objective response and durable remission after treatment with ibrutinib plus rituximab, according to results of a single-center phase 2 study. Jan A. Burger, ...
 Orthopedics Today2 weeks ago RESONATE STUDY: CLL/SLL Survival Improved with Ibrutinib  CancerWatch1 month ago 8/11/14 - IMBRUVICA® ibrutinib Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia CLL and CLL patients with del 17p  Pharmacy Choice1 month ago IMBRUVICA® ibrutinib Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia CLL and CLL patients with del 17p  HispanicBusiness.com1 month ago
[x]  

Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval

The EU approval of Pharmacyclics ( PCYC ) and partner Johnson & Johnson's ( JNJ ) oncology drug Imbruvica (ibrutinib) appears well on track with the European Medicines Agency's ( EMA.TO ) Committee for Medicinal Products for Human Use ( CHMP ) ...
 Yahoo! Finance1 month ago FDA expands approval for Johnson & Johnson, Pharmacyclics' Imbruvica in CLL  FirstWord Pharma1 month ago
[x]  

Ibrutinib and Idelalisib Coming to Europe Soon

Two novel targeted agents that look to change the whole paradigm of treatment for chronic lymphocytic leukemia (CLL) look like they will be available in Europe soon. Ibrutinib ( Imbruvica , Janssen) and idelalisib ( Zydelig , Gilead) have both ...
 Diabetes Care1 month ago Treatment for CLL: Change Aplenty, More Coming  Medscape1 month ago

Pharmacyclics : Special Notice - 65-- Imbruvica (Ibrutinib)

Notice Type: Special Notice Posted Date: 31-JUL-14 Office Address: Department of Veterans Affairs ;SAO West NCO 18 El Paso;Carlos Jaquez, Contracting Officer; 11495 Turner Road ;El Paso TX 79936-1372 Subject: 65-- Imbruvica (Ibrutinib) ...
 4 Traders1 month ago

J&J, Pharmacyclics celebrate yet another nod for leukemia med Imbruvica

Johnson & Johnson's ($JNJ) new blood cancer drug Imbruvica (ibrutinib) is on a roll. The FDA just armed the drug with a new indication in chronic lymphocytic leukemia, adding to a series of regulatory nods. The new use--in patients with a rare ...
 FiercePharma1 month ago JJ Pharmacyclics celebrate yet another nod for leukemia med Imbruvica  Big News Network1 month ago

TG Therapeutics Announces SPA Agreement With FDA for Phase 3 Clinical Trial of TG-1101 (ublituximab) with Imbruvica

NEW YORK, Sept. 15, 2014 -- TG Therapeutics, Inc. announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design, endpoints and statistical analysis ...
 Drugs.com7 hours ago TG Therapeutics enters into agreement with FDA for Phase III CLL trial  Individual.com5 days ago TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patien  Fat Pitch Financials1 week ago TG Therapeutics, Inc. Announces Special Protocol Assessment (SPA) Agreement With The FDA For Its First Phase 3 Clinical Trial Of TG-1101 (Ublituximab) In Combination With Imbruvica(R) (Ibrutinib) For Patients With Previously Treated Chronic Lymphocytic Le  BioSpace1 week ago
[x]  

Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting

GBI Research, the leading business intelligence provider, has released its latest research, ' ', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the ...
 Franklin Credit Management Corporation16 hours ago Market Research Reports, Inc. (www.marketresearchreports.com): Non-Hodgkin Lymphoma Therapeutics in Asia Pacific Markets is Expected to Reach $1.7 Billion by 2020  BusinessWeek4 days ago Australia China : Non-Hodgkin Lymphoma Therapeutics in Asia Pacific Markets Is Expected to Reach $1.7 Billion by 2020  4 Traders3 days ago NHL (Non-Hodgkin Lymphoma) Therapeutics in Asia-Pacific Markets to 2020  Street Sweeper4 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less